Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Registration Number
- NCT04354727
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Safety and Efficacy of Ruxolitinib for COVID-19
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT04348071
Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- University of Jena
- Target Recruit Count
- 193
- Registration Number
- NCT04338958
- Locations
- 🇩🇪
UKSH, Campus Lübeck, Lübeck, Germany
🇩🇪Klinikum der Landeshauptstadt Stuttgart gKöR, Stuttgart, Germany
🇩🇪SRH Wald-Klinikum Gera GmbH, Gera, Germany
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
- Conditions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04337359
Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 3
- Registration Number
- NCT04331665
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- iOnctura
- Target Recruit Count
- 210
- Registration Number
- NCT04328844
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇮🇹Humanitas Research Hospital, Rozzano, Milan, Italy
🇮🇹Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy
Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 48
- Registration Number
- NCT04303403
- Locations
- 🇸🇬
National Cancer Centre, Singapore, Singapore
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 25
- Registration Number
- NCT04282187
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 6
- Registration Number
- NCT04281498
- Locations
- 🇺🇸
Taussig Cancer Center Institute, Cleveland, Ohio, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm Overlap SyndromeMyelodysplastic SyndromeMyeloproliferative NeoplasmRelapsed or Refractory Primary MyelofibrosisSecondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)ET (Essential Thrombocythemia)Myelofibrosis
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 231
- Registration Number
- NCT04279847
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu), Hangzhou, China
🇺🇸University of Alabama At Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.